CN111228293A - Preparation for treating livestock and poultry viral diseases and preparation method thereof - Google Patents
Preparation for treating livestock and poultry viral diseases and preparation method thereof Download PDFInfo
- Publication number
- CN111228293A CN111228293A CN202010169662.7A CN202010169662A CN111228293A CN 111228293 A CN111228293 A CN 111228293A CN 202010169662 A CN202010169662 A CN 202010169662A CN 111228293 A CN111228293 A CN 111228293A
- Authority
- CN
- China
- Prior art keywords
- preparation
- livestock
- poultry
- parts
- viral diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 53
- 201000010099 disease Diseases 0.000 title claims abstract description 46
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 46
- 244000144972 livestock Species 0.000 title claims abstract description 34
- 244000144977 poultry Species 0.000 title claims abstract description 33
- 230000003612 virological effect Effects 0.000 title claims abstract description 32
- 230000000694 effects Effects 0.000 claims abstract description 24
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 24
- 235000006533 astragalus Nutrition 0.000 claims abstract description 23
- 241001061264 Astragalus Species 0.000 claims abstract description 20
- 210000004233 talus Anatomy 0.000 claims abstract description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 20
- 150000004676 glycans Chemical class 0.000 claims abstract description 18
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 18
- 239000005017 polysaccharide Substances 0.000 claims abstract description 18
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims abstract description 14
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims abstract description 12
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 12
- 239000004310 lactic acid Substances 0.000 claims abstract description 12
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims abstract description 12
- 229940001584 sodium metabisulfite Drugs 0.000 claims abstract description 12
- 235000010262 sodium metabisulphite Nutrition 0.000 claims abstract description 12
- 238000001914 filtration Methods 0.000 claims abstract description 11
- 239000008215 water for injection Substances 0.000 claims abstract description 11
- 229960001484 edetic acid Drugs 0.000 claims abstract description 8
- 230000001954 sterilising effect Effects 0.000 claims abstract description 4
- 238000002156 mixing Methods 0.000 claims abstract description 3
- 241000287828 Gallus gallus Species 0.000 claims description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 17
- 241000282898 Sus scrofa Species 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 9
- 208000010359 Newcastle Disease Diseases 0.000 claims description 8
- 206010037660 Pyrexia Diseases 0.000 claims description 7
- 238000000605 extraction Methods 0.000 claims description 7
- 239000000047 product Substances 0.000 claims description 7
- 241001533384 Circovirus Species 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 6
- 230000002458 infectious effect Effects 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 208000007407 African swine fever Diseases 0.000 claims description 4
- 208000009305 pseudorabies Diseases 0.000 claims description 4
- 241000045403 Astragalus propinquus Species 0.000 claims description 3
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims description 3
- 208000002979 Influenza in Birds Diseases 0.000 claims description 3
- 241000125945 Protoparvovirus Species 0.000 claims description 3
- 206010044302 Tracheitis Diseases 0.000 claims description 3
- 239000003708 ampul Substances 0.000 claims description 3
- 206010064097 avian influenza Diseases 0.000 claims description 3
- 238000009835 boiling Methods 0.000 claims description 3
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims description 3
- 201000009837 laryngotracheitis Diseases 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 239000011259 mixed solution Substances 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 3
- 238000005086 pumping Methods 0.000 claims description 3
- 238000007789 sealing Methods 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 208000032625 disorder of ear Diseases 0.000 claims description 2
- 239000004744 fabric Substances 0.000 claims description 2
- 238000005057 refrigeration Methods 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 238000002347 injection Methods 0.000 abstract description 7
- 239000007924 injection Substances 0.000 abstract description 7
- 230000000840 anti-viral effect Effects 0.000 abstract description 4
- 230000007547 defect Effects 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 230000002265 prevention Effects 0.000 abstract description 4
- 229940126678 chinese medicines Drugs 0.000 abstract description 3
- 230000000670 limiting effect Effects 0.000 abstract description 3
- 229940126673 western medicines Drugs 0.000 abstract description 3
- 235000013330 chicken meat Nutrition 0.000 description 23
- 235000013594 poultry meat Nutrition 0.000 description 21
- 241001465754 Metazoa Species 0.000 description 10
- 241000700605 Viruses Species 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 241000282887 Suidae Species 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 8
- 238000000034 method Methods 0.000 description 6
- 210000003437 trachea Anatomy 0.000 description 6
- 230000036528 appetite Effects 0.000 description 5
- 235000019789 appetite Nutrition 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 210000003128 head Anatomy 0.000 description 5
- 210000000214 mouth Anatomy 0.000 description 5
- 241000701063 Gallid alphaherpesvirus 1 Species 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- 210000004712 air sac Anatomy 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 210000000867 larynx Anatomy 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 210000003097 mucus Anatomy 0.000 description 3
- 210000003739 neck Anatomy 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000711404 Avian avulavirus 1 Species 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000027954 Poultry disease Diseases 0.000 description 2
- 210000003484 anatomy Anatomy 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- -1 memantine amines Chemical class 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000007639 printing Methods 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 239000000273 veterinary drug Substances 0.000 description 2
- 244000307697 Agrimonia eupatoria Species 0.000 description 1
- 241000205585 Aquilegia canadensis Species 0.000 description 1
- 235000015763 Artemisia ludoviciana Nutrition 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 206010060976 Bacillus infection Diseases 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000001726 Classical Swine Fever Diseases 0.000 description 1
- 241000710777 Classical swine fever virus Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000037740 Coptis chinensis Species 0.000 description 1
- 241000186227 Corynebacterium diphtheriae Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000608847 Gnaphalium Species 0.000 description 1
- 240000009206 Hemerocallis fulva Species 0.000 description 1
- 235000002941 Hemerocallis fulva Nutrition 0.000 description 1
- 208000032982 Hemorrhagic Fever with Renal Syndrome Diseases 0.000 description 1
- 240000000691 Houttuynia cordata Species 0.000 description 1
- 235000013719 Houttuynia cordata Nutrition 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 241000334160 Isatis Species 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000005342 Porcine Reproductive and Respiratory Syndrome Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 241000607764 Shigella dysenteriae Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 210000003555 cloaca Anatomy 0.000 description 1
- 235000000125 common agrimony Nutrition 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 229940005657 pyrophosphoric acid Drugs 0.000 description 1
- 206010037833 rales Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229940007046 shigella dysenteriae Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229910021654 trace metal Inorganic materials 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/70—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in livestock or poultry
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Biotechnology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Alternative & Traditional Medicine (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a preparation for treating livestock and poultry viral diseases, which is prepared from the following components in parts by weight: 1-3 parts of astragalus polysaccharide, 0.1-0.2 part of sodium metabisulfite, 0.01-0.05 part of ethylene diamine tetraacetic acid, 0.1-0.2 part of lactic acid, 0.05-0.2 part of phenol and 90-99 parts of water for injection; the preparation method comprises the steps of firstly decocting astragalus, then concentrating and extracting, and then concentrating to obtain astragalus polysaccharide, and mixing the prepared astragalus polysaccharide with other components according to a certain proportion, and then filtering, filling and sterilizing to obtain the astragalus polysaccharide. The preparation overcomes the defects of few types, poor broad spectrum and more limiting factors in use of the existing broad-spectrum antiviral injection for livestock and poultry, combines Chinese and western medicines to prepare the preparation for treating the viral diseases of the livestock and poultry, which has good curative effect, strong broad spectrum and easy production, and can be more widely applied to the prevention and treatment of the viral diseases of the livestock and poultry.
Description
Technical Field
The invention belongs to the technical field of veterinary drug production, and particularly relates to a preparation for treating livestock and poultry viral diseases and a preparation method thereof.
Background
The domestic animal husbandry is developed rapidly, and the animal husbandry value is in the forefront all over the world. However, the animal mortality caused by various viral diseases in the breeding process is high, the development of the livestock industry is seriously influenced, and the representative viral diseases of the pigs comprise circovirus diseases, porcine reproductive and respiratory syndrome, pseudorabies, swine fever, parvovirus diseases, African swine fever and the like; the typical viral diseases of poultry include avian influenza, newcastle disease, etc. Viral diseases have become an important problem affecting animal husbandry, especially the african swine fever event that occurs in 2019, causing huge losses to the whole chinese pig breeding industry.
At present, domestic prevention and treatment of livestock and poultry virus diseases are divided into western medicine and traditional Chinese medicine, the western medicine focuses on treatment and takes effect quickly, and the defects of few indications exist commonly in the fields of interferons, amantadine, and memantine amines, antiviral compound medicines, pyrophosphoric acid compound medicines and the like. The traditional Chinese medicine focuses on prevention, has low side effect and slow effect, and has the defect of few indications due to the fact that Chinese herbal medicines such as honeysuckle, isatis root, coptis chinensis, folium isatidis, cudweed herb, houttuynia cordata and the like are used. For example, the prior patent CN201410079560.0 discloses a traditional Chinese medicine composition for treating viral infectious diseases of livestock and poultry, and a preparation method and application thereof. The composition is prepared from 8-24 parts by weight of hispid fig, 10-30 parts by weight of hairyvein agrimony and 6-18 parts by weight of hemerocallis fulva root, is mainly applied to treatment of newcastle disease and porcine pseudorabies, and is small in side effect and safe and convenient to use. However, in general, domestic veterinary drugs contain a lot of antibiotic drugs, although the effect is obvious, serious adverse effects are caused, particularly after the country starts to limit the use of antibiotics in animal husbandry, the effect of treating livestock and poultry diseases by combining Chinese and western medicines is good, the use amount of the antibiotics is low, and the domestic breeding requirements are better met.
Disclosure of Invention
The first technical problem to be solved by the invention is as follows: aiming at the problems of few types, poor broad-spectrum property and multiple limiting factors (factors such as not too large using amount of antibiotics, slow effect of traditional Chinese medicines and the like) of the existing broad-spectrum antiviral injection for livestock and poultry, the preparation for treating the viral diseases of the livestock and poultry with good curative effect and strong broad-spectrum property is provided.
The second technical problem to be solved by the invention is: provides a preparation method of the preparation for treating the livestock and poultry viral diseases, which has mild preparation process and simple method.
In order to solve the technical problems, the technical scheme of the invention is as follows:
a preparation for treating livestock and poultry viral diseases is prepared from the following components in parts by weight:
1-3 parts of astragalus polysaccharide, 0.1-0.2 part of sodium metabisulfite, 0.01-0.05 part of ethylene diamine tetraacetic acid, 0.1-0.2 part of lactic acid, 0.05-0.2 part of phenol and 90-99 parts of water for injection.
Preferably, the weight parts of the components are as follows: 1.5 parts of astragalus polysaccharide, 0.2 part of sodium metabisulfite, 0.03 part of ethylene diamine tetraacetic acid, 0.13 part of lactic acid, 0.1 part of phenol and 98.04 parts of water for injection.
Wherein, the astragalus polysaccharide has obvious effect of resisting tubercle bacillus infection; other components such as amino acids, alkaloids, flavones, etc. have been found to have significant anti-follicular stomatitis virus effects. Animal and transmissible cell experiments show that the astragalus injection has certain blocking effect on Epidemic Hemorrhagic Fever and Virus (EHFV) infection process in mice and suckling mice. Radix astragali has antibacterial effect on in vitro Shigella dysenteriae, Bacillus anthracis, alpha-Streptococcus sanguis, Bacillus diphtheriae, Bacillus pseudodiphtheriae, Diplococcus pneumoniae, Staphylococcus aureus, Staphylococcus citreus, Staphylococcus albus, and Bacillus subtilis.
Sodium metabisulfite is used in printing and dyeing, organic synthesis, printing, tanning, pharmacy and other departments; can be used as antiseptic, bleaching agent, and bulking agent in food processing.
Disodium edetate is an important chelating agent which chelates metal ions in solution. Can be used as heavy metal antidote, complexing agent, antioxidant synergist, stabilizer, softener, etc.; calcium, magnesium and other metal agents, metal masking agents. Preventing discoloration, deterioration, turbidity and oxidation loss of vitamin C caused by metal, and improving oxidation resistance of oil (trace metal such as iron and copper in oil can promote oxidation of oil).
Lactic acid is widely used as a preservative, a carrier agent, a cosolvent, a medicinal preparation, a pH regulator and the like in the aspect of medicine, and has the restriction effects of regulating muscle activity and resisting fatigue.
Phenol is an important raw material for the production of certain resins, bactericides, preservatives and drugs (e.g. aspirin) and can denature proteins. The benzene ring structure of the phenol molecule is highly similar to the six-membered heterocyclic ring structure of the pyrimidine ring in viral DNA or RNA.
A preparation method of a preparation for treating livestock and poultry viral diseases comprises the following steps:
a. preparing astragalus polysaccharide: placing the astragalus membranaceus traditional Chinese medicinal materials into an extraction tank, adding 8-10 times of water, decocting for 3 hours at the decocting temperature of 90-105 ℃, filtering by using a 200-mesh filter screen, pumping the filtered liquid medicine into a concentration tank, concentrating until the relative density is 1.15-1.20, conveying into a precipitation tank, extracting by using methanol, ethanol or propylene glycol, standing for 24 hours, adding 8 times of water into the filtered precipitate again, adding water, boiling for 15 minutes, filtering by using a 200-mesh filter cloth plate frame again, conveying the filtrate into the concentration tank, concentrating until the relative density is 1.15-1.20, and refrigerating for later use;
b. b, fully mixing the product obtained in the step a and a product added subsequently in a proportioning tank according to the weight parts of 1-3 parts of astragalus polysaccharide, 0.1-0.2 part of sodium metabisulfite, 0.01-0.05 part of disodium ethylene diamine tetraacetate, 0.1-0.2 part of lactic acid and 0.05-0.2 part of phenol, adding 90-99 parts of water for injection, and uniformly stirring to prepare the mixture;
c. and c, filtering the mixed solution obtained in the step b by using a filter element with the diameter of 0.22-0.3 mu m, injecting the filtrate into a sterilized ampoule bottle, sealing, and sterilizing again to obtain the product.
Preferably, the concentration in the step a is double-effect concentration by using a double-effect concentrator, wherein the vacuum degree of the I effect is controlled to be-0.04 to-0.02 Mpa, and the temperature is controlled to be 70 to 90 ℃; controlling the II-effect vacuum degree to be-0.08 to-0.05 Mpa and the temperature to be 50 to 60 ℃.
Preferably, the extraction reagent in the step a is ethanol, and the addition amount of the ethanol during extraction is 70-80% of the total weight.
Preferably, the refrigeration in the step a is below 4 ℃.
The preparation prepared by the invention can be applied to the treatment of livestock and poultry viral diseases such as avian infectious laryngotracheitis, circovirus disease, blue-ear disease, pseudorabies, swine fever, parvovirus disease, African swine fever, avian influenza, Newcastle disease and the like.
Due to the adoption of the technical scheme, the invention has the beneficial effects that:
1. the preparation for treating the viral diseases of the livestock and the poultry adopts a Chinese and Western combination scheme, and the astragalus polysaccharide is proved to be a traditional Chinese medicine extract with obvious effect through a large amount of researches, and can promote immune cells to generate interferon, enhance the immunity of animal organisms and promote the growth of animals; phenol makes base pairing of viruses wrong through competitive inhibition, thereby achieving the aim of partially killing the viruses; the organic combination of the two can quickly and accurately carry out chemical induction virus killing on the basis of activating autoimmunity, and killed viruses become inactivated vaccines and strengthen the immune system of an organism again, so that the organism can overcome various viruses, and the preparation has broad-spectrum therapeutic performance;
2. the preparation method has the advantages of mild preparation process and simple method, and can be used for large-scale industrial production.
In a word, the invention overcomes the defects of few types, poor broad spectrum and more limiting factors in use of the existing broad-spectrum antiviral injection for livestock and poultry, combines Chinese and western medicines, prepares the preparation for treating the viral diseases of the livestock and poultry with good curative effect, strong broad spectrum and easy production, and can be more widely applied to the prevention and treatment of the viral diseases of the livestock and poultry.
Detailed Description
The invention is further illustrated by the following examples.
Example one
A preparation for treating livestock and poultry viral diseases is prepared from the following components in parts by weight: 2 parts of astragalus polysaccharide, 0.1 part of sodium metabisulfite, 0.01 part of ethylene diamine tetraacetic acid, 0.1 part of lactic acid, 0.05 part of phenol and 98.73 parts of water for injection.
Example two
A preparation for treating livestock and poultry viral diseases is prepared from the following components in parts by weight: 3 parts of astragalus polysaccharide, 0.2 part of sodium metabisulfite, 0.05 part of ethylene diamine tetraacetic acid, 0.2 part of lactic acid, 0.2 part of phenol and 96.35 parts of water for injection.
EXAMPLE III
A preparation for treating livestock and poultry viral diseases is prepared from the following components in parts by weight: 1.5 parts of astragalus polysaccharide, 0.2 part of sodium metabisulfite, 0.03 part of ethylene diamine tetraacetic acid, 0.13 part of lactic acid, 0.1 part of phenol and 98.04 parts of water for injection.
Example four
A preparation method of a preparation for treating livestock and poultry viral diseases comprises the steps of putting astragalus membranaceus traditional Chinese medicinal materials into an extraction tank, adding 8-10 times of water, decocting for 3 hours at the decocting temperature of 90-105 ℃, filtering through a 200-mesh filter screen, pumping filtered liquid medicine into a concentration tank, concentrating until the relative density is 1.15-1.20, conveying into a precipitation tank, adding ethanol until the ethanol accounts for 70-80% of the total weight, standing for 24 hours, adding 8 times of water into the precipitate after filtering, adding water, boiling for 15 minutes, filtering through a 200-mesh filter screen frame again, conveying the filtrate into a concentration tank, and concentrating until the relative density is 1.15-1.20. Refrigerating in a refrigerating room (below 4 deg.C).
Then, a certain amount of astragalus polysaccharide, sodium metabisulfite, disodium ethylene diamine tetraacetate, lactic acid and phenol are taken according to the proportion of the third embodiment and mixed in a batching tank, and a certain amount of water for injection is added and stirred uniformly. Filtering the mixed solution by a filter element with the diameter of 0.22 mu m, injecting the filtrate into a sterilized ampoule bottle, sealing, and sterilizing again to obtain the product.
Experimental example 1
The formulation prepared in example four was used in the treatment of the infectious chicken laryngotracheitis test:
1. strain: infectious laryngotracheitis virus ILTV Wang gang strain E4
2. The test chicken: 50 AA chickens 35 days old were purchased from local chickens cooperative and immunized according to a normal immunization program except that ILT and infectious bronchitis vaccines were not inoculated.
3. The kit for detecting the infectious bronchitis antibody is purchased from Beijing Aidejinghuan Henry biotechnology limited.
4. The experimental method comprises the following steps: 50 test chickens were randomly divided into 2 groups of experimental and control groups of 25 chickens each. In the experimental group, 0.2mL of ILTV virus infection solution was injected into each chicken trachea. After the virus attack, the clinical manifestations of the chickens were observed every day, and pathological anatomy was performed on the dead chickens, mainly to observe the pathological changes of the nasal cavity, larynx, trachea and air sac. When clinical symptoms appear in the tested chicken, the preparation prepared in the fourth embodiment is injected for 1 time every day, the medicine is continuously applied for 3 days, and the observation is carried out for 10 days.
5. The experimental results are as follows: the infected group has respiratory tract symptoms after 18 hours of toxin attack, the disease rate is 100 percent, symptoms such as mouth stretching and neck breathing, head swinging, cough and the like appear, listlessness, crowding and piling, inappetence and disappearing appetite of individual chickens. The pathological changes of the autopsy are seen that yellow cheese-like exudates or blood-carrying mucus exist in the larynx and the trachea, blood clots exist in the trachea of individual chickens, the bleeding is obvious, the air sac is turbid, and the lungs are congested and bleed; the blank control chicken was not abnormal. After the medicine is taken, respiratory symptoms are obviously relieved, 21 patients recover health after 5 days, and 4 patients die. The cure rate is more than 80%. Specific data are detailed in table 1:
TABLE 1 clinical manifestations of two groups of subjects
As can be seen from Table 1, the clinical efficacy of the preparation prepared in the experimental group by injecting the fourth preparation in the example on infectious laryngotracheitis virus infection is determined, the effect of the preparation is obviously superior to that of the experimental control group, and the difference is very significant compared with the control group (P is less than 0.01).
Experimental example two
The formulation prepared using example four was used for the treatment of newcastle disease:
1. strain: F48E9 virulent strain, ELD50105.0/0.1mL, and is separated, purified and stored by poultry disease laboratory of Life sciences college of Shandong university.
2. The test chicken: 40 non-immunized AA chickens at 1 day of age were purchased from local chicken cooperative.
3. The experimental method comprises the following steps: 40 test chickens were randomly divided into 2 groups of experimental and control groups of 20 chickens each. In the experimental group, 0.2mL of F48E9 virus infection solution was injected into each chicken trachea. After the virus attack, the clinical manifestations of the chickens were observed every day, and pathological anatomy was performed on the dead chickens, mainly to observe the pathological changes of the nasal cavity, larynx, trachea and air sac. When clinical symptoms appear in the tested chicken, the preparation prepared in the fourth embodiment is started, 1 time per day, the medicine is continuously applied for 3 days, and 10 days are observed.
5. The experimental results are as follows: after the Newcastle disease attacks the toxin, the sick chicks are half-closed or fully closed and are in a sleeping state, and the sick chicks are driven or frightened to move, the heads and the necks are curled, the tail wings are drooped, the food is wasted, the body temperature is raised in the early stage of the disease, and the drinking water is increased; however, when the disease condition is aggravated and the disease is drunk wastefully, the beard and flesh are purple blue or purple black, the crop speak in a low voice is filled with hardened and undigested feed or acid and odorous liquid, the corners of the mouth often have secretion flowing out, the mouth is difficult to breathe and has rale, the mouth and the neck are stretched, meanwhile, strange cry is emitted, the dysentery is caused, the excrement is yellow green, and a large amount of mucus is mixed in the excrement. After the dissection, the oral cavity is full of mucus, and the crop speak in a low voice is full of hardened feed or full of gas and liquid; cloaca congestion, hemorrhage, necrosis, erosion with fecal contamination; it can be judged as typical Newcastle disease. The specific data are detailed in table 2:
TABLE 2 clinical manifestations of two groups of subjects
As can be seen from Table 2, the clinical efficacy of the formulation prepared in the experimental group by injecting the fourth example on Newcastle disease virus infection is determined, the effect is obviously better than that of the experimental control group, and the difference is very significant compared with the control group (P < 0.01).
Experimental example III
The formulation prepared in example four was used for the treatment of swine fever:
1. test animals: in a pig farm, 30 fattening pigs clinically diagnosed as classical swine fever are selected, the weight is 20-30kg, the fattening pigs are averagely divided into 2 groups, and each group has 15 fattening pigs.
2. Test protocol: the preparation is administered by intramuscular injection with 3ml per injection for 1 time per day for 3 days, and the results are observed.
3. And (3) judging the treatment effect:
and (3) curing: after the pig is taken, the spirit and the appetite are recovered to be normal, no fever symptom exists, and the relapse does not occur within 15 days.
The method has the following advantages: after the pig is taken, the spirit and the appetite are obviously improved, and the symptoms of fever, diarrhea and asthma are relieved.
And (4) invalidation: the pig died.
4. Clinical results: after the preparation prepared in the fourth embodiment is injected, 1 and 2 dead pigs in a test group are obviously improved, and the rest 12 pigs are completely cured, so that the effective rate reaches over 93 percent and the cure rate reaches 80 percent. Specific data are detailed in table 3:
TABLE 3 clinical manifestations of two groups of subjects
Experimental example four
The preparation prepared in example four was used for the treatment of circovirus disease:
1. test animals: in a pig farm, 40 fattening pigs with confirmed clinical diagnosis of the circovirus disease are selected, the weight is 20-30kg, the fattening pigs are averagely divided into 2 groups, and each group has 20 fattening pigs.
2. Test protocol: the preparation is administered by intramuscular injection with 3ml per injection for 1 time per day for 3 days, and the results are observed.
3. And (3) judging the treatment effect:
and (3) curing: after the pig is taken, the spirit and the appetite are recovered to be normal, no fever symptom exists, and the relapse does not occur within 15 days.
The method has the following advantages: after the pig is taken, the spirit and the appetite are obviously improved, and the whole body is bluish purple, the nasal foam and the high temperature of the body are relieved.
And (4) invalidation: the pig died.
4. Clinical results: after the injection preparation is injected, the number of dead heads is 2, 2 dead heads are obviously lightened, and the rest 16 dead heads are completely cured, and the cure rate is 80%. The specific data are detailed in table 4:
TABLE 4 clinical manifestations of two groups of subjects
As can be seen from the above experimental examples one to four, the preparation for treating viral diseases of livestock and poultry has obvious curative effects on the treatment of infectious laryngotracheitis, newcastle disease, swine fever and circovirus disease of chicken, and obtains better results for experiments of other related diseases, and experimental data are not listed herein. Experiments show that the Chinese medicinal composition has the advantages of good curative effect and strong broad spectrum, and can be widely applied to treatment of livestock and poultry viral diseases.
It should be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the present invention. Further, it should be understood that various changes or modifications of the present invention may be made by those skilled in the art after reading the teaching of the present invention, and such equivalents may fall within the scope of the present invention as defined in the appended claims.
Claims (7)
1. The preparation for treating the viral diseases of the livestock and the poultry is characterized by being prepared from the following components in parts by weight:
1-3 parts of astragalus polysaccharide, 0.1-0.2 part of sodium metabisulfite, 0.01-0.05 part of ethylene diamine tetraacetic acid, 0.1-0.2 part of lactic acid, 0.05-0.2 part of phenol and 90-99 parts of water for injection.
2. The preparation for treating livestock and poultry viral diseases according to claim 1, which is characterized in that: the weight parts of the components are as follows: 1.5 parts of astragalus polysaccharide, 0.2 part of sodium metabisulfite, 0.03 part of ethylene diamine tetraacetic acid, 0.13 part of lactic acid, 0.1 part of phenol and 98.04 parts of water for injection.
3. The preparation method of the preparation for treating the viral diseases of the livestock and the poultry is characterized by comprising the following steps:
a. preparing astragalus polysaccharide: placing the astragalus membranaceus traditional Chinese medicinal materials into an extraction tank, adding 8-10 times of water, decocting for 3 hours at the decocting temperature of 90-105 ℃, filtering by using a 200-mesh filter screen, pumping the filtered liquid medicine into a concentration tank, concentrating until the relative density is 1.15-1.20, conveying into a precipitation tank, extracting by using methanol, ethanol or propylene glycol, standing for 24 hours, adding 8 times of water into the filtered precipitate again, adding water, boiling for 15 minutes, filtering by using a 200-mesh filter cloth plate frame again, conveying the filtrate into the concentration tank, concentrating until the relative density is 1.15-1.20, and refrigerating for later use;
b. b, fully mixing the product obtained in the step a and a product added subsequently in a proportioning tank according to the weight parts of 1-3 parts of astragalus polysaccharide, 0.1-0.2 part of sodium metabisulfite, 0.01-0.05 part of disodium ethylene diamine tetraacetate, 0.1-0.2 part of lactic acid and 0.05-0.2 part of phenol, adding 90-99 parts of water for injection, and uniformly stirring to prepare the mixture;
c. and c, filtering the mixed solution obtained in the step b by using a filter element with the diameter of 0.22-0.3 mu m, injecting the filtrate into a sterilized ampoule bottle, sealing, and sterilizing again to obtain the product.
4. The preparation method of the preparation for treating the livestock and poultry viral diseases according to claim 3, which is characterized by comprising the following steps: the concentration in the step a is double-effect concentration, wherein the degree of vacuum of the effect I is controlled to be-0.04 to-0.02 Mpa, and the temperature is controlled to be 70 to 90 ℃; controlling the II-effect vacuum degree to be-0.08 to-0.05 Mpa and the temperature to be 50 to 60 ℃.
5. The preparation method of the preparation for treating the livestock and poultry viral diseases according to claim 3, which is characterized by comprising the following steps: the extraction reagent in the step a is ethanol, and the addition amount of the ethanol during extraction is 70-80% of the total weight.
6. The preparation method of the preparation for treating the livestock and poultry viral diseases according to claim 3, which is characterized by comprising the following steps: the refrigeration in the step a is below 4 ℃.
7. The application of the preparation for treating the viral diseases of the livestock and the poultry is characterized in that: the preparation is applied to the treatment of circovirus disease, blue-ear disease, pseudorabies, swine fever, parvovirus disease, African swine fever, avian influenza, Newcastle disease and infectious laryngotracheitis of chicken.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010169662.7A CN111228293A (en) | 2020-03-12 | 2020-03-12 | Preparation for treating livestock and poultry viral diseases and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010169662.7A CN111228293A (en) | 2020-03-12 | 2020-03-12 | Preparation for treating livestock and poultry viral diseases and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111228293A true CN111228293A (en) | 2020-06-05 |
Family
ID=70869377
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010169662.7A Pending CN111228293A (en) | 2020-03-12 | 2020-03-12 | Preparation for treating livestock and poultry viral diseases and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111228293A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101088521A (en) * | 2006-06-14 | 2007-12-19 | 北京四环科宝制药有限公司 | Astragalus medicine prepn and its prepn process |
| CN107802651A (en) * | 2016-09-08 | 2018-03-16 | 潍坊华英生物科技有限公司 | Inactivate application of the lactic acid bacteria in viral disease medicine is prevented and treated |
| CN108743523A (en) * | 2018-06-11 | 2018-11-06 | 滕川 | A kind of astragalus polyose preparation and its preparation method and application |
| CN110559363A (en) * | 2019-10-15 | 2019-12-13 | 郑州赛科药业科技有限公司 | Traditional Chinese medicine compound fermented oral liquid for preventing and treating African swine fever and preparation process thereof |
-
2020
- 2020-03-12 CN CN202010169662.7A patent/CN111228293A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101088521A (en) * | 2006-06-14 | 2007-12-19 | 北京四环科宝制药有限公司 | Astragalus medicine prepn and its prepn process |
| CN107802651A (en) * | 2016-09-08 | 2018-03-16 | 潍坊华英生物科技有限公司 | Inactivate application of the lactic acid bacteria in viral disease medicine is prevented and treated |
| CN108743523A (en) * | 2018-06-11 | 2018-11-06 | 滕川 | A kind of astragalus polyose preparation and its preparation method and application |
| CN110559363A (en) * | 2019-10-15 | 2019-12-13 | 郑州赛科药业科技有限公司 | Traditional Chinese medicine compound fermented oral liquid for preventing and treating African swine fever and preparation process thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1895342A (en) | Fowl anticoccidial medicinal composition and its preparation | |
| CN100586454C (en) | Chinese medicine composition for birds, preparing method and application of the same | |
| CN102670694B (en) | Traditional Chinese medicine combination for treating porcine pseudorabies and preparation method and application thereof | |
| CN107661416A (en) | A kind of traditional Chinese medicine extraction compound pharmaceutical for preventing and treating livestock and birds respiratory disease | |
| CN111228293A (en) | Preparation for treating livestock and poultry viral diseases and preparation method thereof | |
| CN102743407B (en) | Oral liquid for treating infectious air sacculitis of chicken and preparation method thereof | |
| CN114377127B (en) | Triple egg yolk antibody preparation and preparation method and application thereof | |
| CN105693854A (en) | Preparation method of refined yolk antibody against duck tembusu virus | |
| CN105012946A (en) | Pasteurellosis and duck colibacilosis combined propolis inactivated vaccine and preparation method thereof | |
| CN103784685B (en) | Chinese medicine composition for the treatment of livestock and poultry virus sexually transmitted disease and its preparation method and application | |
| CN111568861A (en) | Bromhexine hydrochloride oral liquid for livestock and poultry as well as preparation method and application thereof | |
| CN104306629B (en) | A kind of Chinese medicine composition of chicken colibacillosis resisting disease and preparation method thereof | |
| CN105412254A (en) | Traditional Chinese medicine composition for preventing and treating infectious diseases of respiratory tracts of livestock and preparation method thereof | |
| CN107158067B (en) | Traditional Chinese medicine composition for preventing and treating swine eperythrozoonosis and preparation method and application thereof | |
| CN105232469B (en) | A kind of Thiamphenicol soluble powder and preparation method thereof | |
| CN116650577B (en) | Application of calyx seu fructus physalis extract in resisting infectious bronchitis virus | |
| CN115252668B (en) | Application of senecio scandens water extract as unique active ingredient in preparation of oral medicine for preventing and treating colibacillosis of chicken-eating type | |
| CN103611156A (en) | Avian pentavalent vaccine and preparation method thereof | |
| CN103272240A (en) | Composite heat protectant for specific transfer factor of nephropathogenic infectious bronchitis, and application thereof | |
| CN108310140A (en) | It is a kind of to be used to prevent pharmaceutical composition of infectious laryngotracheitis of chicken and its preparation method and application | |
| CN107233397A (en) | A kind of compound isatis-root injection and preparation method thereof | |
| CN106963822A (en) | Prevent and treat Chinese medicine composition of infectious bronchitis of chicken and its preparation method and application | |
| CN113786413A (en) | Application of chaenomeles speciosa polysaccharide in preparation of antiviral drugs | |
| CN112494543A (en) | Shuanghuanglian powder injection for animals and preparation method thereof | |
| CN101129347A (en) | Florfenicol oil emulsion injection and method for formulating the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200605 |
|
| RJ01 | Rejection of invention patent application after publication |